Lymphoma / Multiple Myeloma

Lymphoma / Multiple Myeloma

Topic Summary

The role of pharmacists in the delivery of cancer care has changed significantly in Ireland over recent years. These changes are largely due to increases in the use of chemotherapy as a result of the aging population, and supportive therapy for the management of side effects and co-morbidities.  The overarching goal of the course is to educate pharmacists on the basics of lymphoma; non-Hodgkin’s lymphoma and multiple myeloma to better prepare them to recognize and treat these conditions within their clinical practice, to improve patient outcomes, and to be successful. Adverse prognostic factors including time to relapse, poor performance status, advanced stages at relapse and anemia have been shown to have an impact on survival and freedom from second relapse. This educational activity will review the newer treatment options for newly diagnosed patients taking into consideration recent guideline recommendations. Strategies for the management of patients who develop adverse effects and treatment complications will also be explained.


learning Objective

  • Review the pathophysiology and epidemiology of lymphoma; non-Hodgkin’s lymphoma and multiple myeloma.
  • Outline the most appropriate screening and prevention strategy for non-Hodgkin’s lymphoma, Hodgkin’s disease, and multiple myeloma.
  • List the prognostic factors non-Hodgkin’s lymphoma, Hodgkin’s disease, and multiple myeloma and their influence on survival and therapy.
  • Discuss the standard regimens for management of lymphoma; non-Hodgkin’s lymphoma and multiple myeloma.
  • Identify common drug therapy regimens used for initial treatment of lymphoma; non-Hodgkin’s lymphoma and multiple myeloma.
  • For lymphomas and multiple myeloma, list potential chemotherapy, immunotherapy, and antiangiogenesis regimens along with their response rates, toxicities, and how to monitor for response and toxicity.
  • Describe the clinical impact of emerging data on the future treatment of patients with lymphoma; non-Hodgkin’s lymphoma and multiple myeloma.

Topic Modules

Content

Etiology , Clinical presentation

Pathology , Screening

Diagnosis , Risk factors

Treatment , Response Criteria

Supportive Care , Novel Agents

Etiology , Clinical Presentation

Pathology , Screening

Diagnosis , Risk Factors

Treatment , Response Criteria

I.V Mixing , Supportive Care , Novel Agents

Topic Instructors

loader